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Abstract
Background: Bone marrow-derived stromal cells (MSC) are attractive targets for ex vivo cell and
gene therapy. In this context, we investigated the feasibility of a plasmid-based strategy for genetic
modification of human (h)MSC with enhanced green fluorescent protein (EGFP) and neurotrophin
(NT)3. Three genetically modified hMSC lines (EGFP, NT3, NT3-EGFP) were established and used
to study cell survival and transgene expression following transplantation in rat spinal cord.
Results: First, we demonstrate long-term survival of transplanted hMSC-EGFP cells in rat spinal
cord under, but not without, appropriate immune suppression. Next, we examined the stability of
EGFP or NT3 transgene expression following transplantation of hMSC-EGFP, hMSC-NT3 and
hMSC-NT3-EGFP in rat spinal cord. While in vivo EGFP mRNA and protein expression by
transplanted hMSC-EGFP cells was readily detectable at different time points post-transplantation,
in vivo NT3 mRNA expression by hMSC-NT3 cells and in vivo EGFP protein expression by hMSC-
NT3-EGFP cells was, respectively, undetectable or declined rapidly between day 1 and 7 post-
transplantation. Further investigation revealed that the observed in vivo decline of EGFP protein
expression by hMSC-NT3-EGFP cells: (i) was associated with a decrease in transgenic NT3-EGFP
mRNA expression as suggested following laser capture micro-dissection analysis of hMSC-NT3-
EGFP cell transplants at day 1 and day 7 post-transplantation, (ii) did not occur when hMSC-NT3-
EGFP cells were transplanted subcutaneously, and (iii) was reversed upon re-establishment of
hMSC-NT3-EGFP cell cultures at 2 weeks post-transplantation. Finally, because we observed a
slowly progressing tumour growth following transplantation of all our hMSC cell transplants, we
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here demonstrate that omitting immune suppressive therapy is sufficient to prevent further tumour
growth and to eradicate malignant xenogeneic cell transplants.
Conclusion: In this study, we demonstrate that genetically modified hMSC lines can survive in
healthy rat spinal cord over at least 3 weeks by using adequate immune suppression and can serve
as vehicles for transgene expression. However, before genetically modified hMSC can potentially
be used in a clinical setting to treat spinal cord injuries, more research on standardisation of hMSC
culture and genetic modification needs to be done in order to prevent tumour formation and
transgene silencing in vivo.
Background
Despite major progress in pharmacological and surgical
approaches, a spinal cord injury still remains a very com-
plex medical and psychological challenge, both for
patients and their relatives as well as for involved physi-
cians, with currently no existing curative therapy. Next to
primary care using surgical osteosynthesis techniques and
administration of methylprednisolone [1], further thera-
peutic approaches are mainly supportive and are focussed
on prevention of secondary complications, like urological
problems, decubitus, respiratory tract pathology, etc...
However, during the past decade, significant progress has
been made in animal models of spinal cord injury [2,3],
and more therapeutic strategies are likely to be discovered
as the existence of an endogenous neural regenerative
mechanism in the central nerve system is now generally
accepted [4,5]. In this context, a spinal cord injury should
not be seen as a single event, but must be recognized as an
evolving process with different stages for which different
therapeutic approaches can be developed [6]. In general,
functional outcome following spinal cord injury will
highly depend on the severity of both primary anatomical
disruption of nerve tracts (due to contusion, laceration,
penetration, etc.) and secondary damage [7] caused by
inevitable inflammatory reactions following the initial
trauma. In brief, these secondary inflammatory responses
mainly consist of an influx of peripheral inflammatory
cells (macrophages, T-cells) and an activation of resident
microglia. This inflammatory reaction will finally result in
the formation of a central cavitation at the site of the ini-
tial trauma in the spinal cord surrounded by glial scar tis-
sue. The latter is an important physical and chemical
barrier for endogenous regeneration of ascending and
descending nerve tracts and thereby compromises func-
tional outcome. The development of future curative treat-
ments will therefore need to combine multiple
approaches that are able to modulate secondary inflam-
mation and to enhance endogenous regeneration.
Currently, a very promising experimental strategy for pro-
moting neuronal survival and endogenous regeneration
in injured spinal cord is local delivery of neurotrophic fac-
tors. Several neurotrophic factors, like brain-derived neu-
rotrophic factor (BDNF), glial cell-derived neurotrophic
factor (GDNF), neurotrophin (NT)3 and nerve growth
factor (NGF), can stimulate neurogenesis in vitro and in
vivo [8], and their importance for the development of the
nervous system, for axonal pathfinding and neuronal sur-
vival has made them promising targets to augment regen-
eration in the injured brain and spinal cord [9,10]. Several
approaches have been reported to deliver these neuro-
trophic factors into injured spinal cord: direct injection
[11], adenoviral vectors [12], osmotic minipumps [13-
15], fibrin glue [16], hydrogels [17] and genetically mod-
ified cell transplants [9,18-20]. Safety, efficacy and appli-
cability of these reported methodologies highly differ
between the above-referenced and other published
reports, implying the need for continuous study, improve-
ment and validation of in vivo delivery systems for neuro-
trophic factors in spinal cord.
In this study, we investigated the feasibility of a plasmid-
based strategy for in vitro genetic modification of human
bone marrow-derived stromal cells (hMSC) with
enhanced green fluorescent protein (EGFP) and NT3.
Three genetically modified hMSC lines (EGFP, NT3, NT3-
EGFP) were established and used to study cell survival and
transgene expression following transplantation in rat spi-
nal cord. First, we present a number of optimised and easy
to implement techniques for reproducible histological
and molecular detection of hMSC cell transplants in rat
spinal cord. Using these techniques we demonstrate that
genetically modified hMSC lines can survive in healthy rat
spinal cord when using adequate immune suppression
and can serve as vehicles for in vivo transgene expression.
However, transgene silencing and tumour formation by
hMSC cell transplants in vivo are of utmost importance
and should therefore be addressed in priority in future
research.
Results
In vitro characterisation of genetically modified hMSC cell 
transplants
A human bone marrow-derived stromal cell line (hMSC)
was genetically modified with DNA plasmids encoding
either (i) enhanced green fluorescent protein (EGFP)
alone, (ii) neurotrophin-3 (NT3) alone, or (iii) both
EGFP and NT3, as described in the Materials and MethodsBMC Biotechnology 2007, 7:90 http://www.biomedcentral.com/1472-6750/7/90
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section. All three plasmids used for genetic modification
were based on the same backbone vector and are shown
in Figure 1A. The three genetically modified hMSC lines
that were established for use in this study are designated
as: hMSC-EGFP, hMSC-NT3 and hMSC-NT3-EGFP.
Before transplantation experiments were carried out,
transgene expression of these genetically modified hMSC
lines was characterised at several passages during culture
by PCR, real-time PCR, ELISA and flow cytometry. Figure
1B shows a representative example for the detection of
transgenic EGFP and NT3 DNA and mRNA by standard
PCR and RT-PCR analysis on DNA and mRNA isolated
from the different hMSC lines used in this study. In addi-
tion, Figure 1C shows a representative example for the
detection of transgenic EGFP and/or NT3 mRNA by real-
time RT-PCR analysis on mRNA isolated from all hMSC
lines used in this study. With regard to protein expression,
Figure 1D shows a representative ELISA measurement of
NT3 secretion by the different hMSC lines used in this
study and Figure 1E shows a representative flow cytomet-
ric analysis of EGFP expression by the EGFP expressing
hMSC lines used in this study.
Immunological survival of hMSC-EGFP cell transplants in 
rat spinal cord
Several reports [21-24] ascribe specific immune modulat-
ing and immune privileged features to hMSC, suggesting
that these cells might serve as a universal off-the-shelf
source of cells for use in regenerative medicine and can be
transplanted into an allogeneic and xenogeneic host with-
out the need for immune suppressive therapy. In order to
investigate whether our established hMSC line has
immune modulating properties, two series of transplanta-
tion experiments were performed using hMSC genetically
modified with the EGFP reporter gene (Figure 1). First,
hMSC-EGFP were transplanted in healthy rat spinal cord
without systemic immune suppression. At different time
points post-transplantation, animals were sacrificed and
extracted spinal cords were analysed by histology for cell
transplant survival, EGFP transgene expression and mac-
rophage invasion, as presented in Figure 2A. Although on
day 1 and week 1 post-transplantation hMSC-EGFP cell
transplants were clearly visible by direct EGFP fluores-
cence and immuno-histochemical staining for EGFP,
from 2 weeks post-transplantation the whole transplanta-
tion site was invaded with CD68+ macrophages and nei-
ther direct EGFP fluorescence nor immuno-histochemical
staining for EGFP could indicate the immunological sur-
vival of transplanted hMSC-EGFP cells. Interestingly,
despite this extensive inflammatory reaction associated
with transplant rejection, no negative adverse effects were
seen on general health status and locomotion of the cell
transplanted animals (data not shown). Next, in order to
prevent immunological rejection of hMSC-EGFP cell
transplants, the same transplantation experiment was per-
formed but with daily subcutaneous administrations of
10 mg/kg cyclosporine A starting 3 days prior to trans-
plantation. In contrast to the results described above, effi-
cient transplant survival was observed in all cell-
transplanted animals at different time points post-trans-
plantation. Representative examples of molecular and his-
tological detection of hMSC-EGFP cell transplants in
spinal cord are shown in Figure 2B. Following DNA and
mRNA isolation from dissected spinal cord segments,
PCR and RT-PCR analysis allowed to detect hMSC-EGFP
cell transplants (week 3, PCR for EGFP on isolated DNA)
and their transgene expression (week 3, RT-PCR for EGFP
on isolated mRNA). In addition, real-time RT-PCR analy-
sis confirmed EGFP transgene expression in spinal cord
(day 1, real-time RT-PCR for EGFP on isolated mRNA).
Moreover, this molecular observation of hMSC-EGFP cell
transplant survival in rat spinal cord and persisting trans-
gene expression at different time points post-transplanta-
tion was also proven by histological analysis (week 1 and
2, direct EGFP fluorescence and immuno-histochemical
staining for EGFP). In summary, based on the above-
described observations, all further transplantation experi-
ments were performed under immune suppression.
Transgene expression of hMSC-NT3 cell transplants in rat 
spinal cord
Following genetic modification of hMSC with a DNA
plasmid encoding the EGFP reporter gene and successful
in vivo transplantation and detection of hMSC-EGFP cells,
we genetically modified hMSC with a similar DNA plas-
mid-encoding rat NT3 (see Figure 1A, pCMV-NT3 plas-
mid). In contrast to the procedures followed for obtaining
the presented hMSC-EGFP line (i.e. combined antibiotics
selection and cell sorting, see Materials and Methods),
obtaining a pure transgene expressing hMSC-NT3 line was
not possible through cell sorting, due to the lack of a flu-
orescent marker molecule (e.g. EGFP). Therefore, follow-
ing antibiotics selection, single clones were grown and
screened by ELISA for highest production of NT3 (Figure
1D, hMSC-NT3 cells). Despite significant production of
NT3 by the selected hMSC-NT3 clone, only very low, but
however significant, NT3 mRNA was produced by these
cells (Figure 1C, hMSC-NT3 cells). However, due to this
low level of NT3 mRNA produced by transgenic hMSC-
NT3 cells, NT3 transgene expression following transplan-
tation of hMSC-NT3 cells in rat spinal cord could not be
detected (Figure 3). In summary, based on the above-
described observations, cell sorting for an EGFP reporter
gene needs to be included for further genetic modification
experiments in order to obtain a transgenic cell popula-
tion producing high levels of transgenic mRNA.BMC Biotechnology 2007, 7:90 http://www.biomedcentral.com/1472-6750/7/90
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In vitro characterisation of genetically modified hMSC cell transplants Figure 1
In vitro characterisation of genetically modified hMSC cell transplants. (A) Plasmid DNA constructs used for genetic 
modification of human bone marrow-derived stromal cells (hMSC) in order to obtain hMSC-EGFP, hMSC-NT3 and hMSC-
NT3-EGFP cell populations. CMV: Cytomegalovirus immediate early promotor + enhancer. EGFP: enhanced green fluorescent 
protein. pA: SV40 early mRNA polyadenylation signal. NT3: neurothrophin-3. IRES: internal ribosome entry site. (B) Repre-
sentative standard PCR and RT-PCR analysis on DNA and mRNA isolated from the different genetically modified hMSC popu-
lations used in this study (see numbers below pictures) indicating the presence of transgenic EGFP and/or NT3 DNA and 
mRNA sequences. M: length marker. GAPDH: glyceraldehyde-3-phosphate dehydrogenase. (C) Representative real-time RT-
PCR analysis on mRNA isolated from the different genetically modified hMSC populations used in this study (see numbers 
below pictures) showing quantitative differences in the level of transgenic EGFP and/or NT3 mRNA transcripts/1000 copies 
GAPDH; nd: no data available. (D) Representative ELISA measurement on supernatant samples from the different genetically 
modified hMSC populations used in this study (see numbers below pictures) showing quantitative differences in the level of 
NT3 secretion in picogram/105 cells/24 hours. (E) Representative flow cytometric analysis of EGFP expression by hMSC-EGFP 
and hMSC-NT3-EGFP populations showing quantitative differences in the level of transgenic EGFP protein expression. SSC: 
side scatter.BMC Biotechnology 2007, 7:90 http://www.biomedcentral.com/1472-6750/7/90
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Immunological survival of hMSC-EGFP cell transplants in rat spinal cord Figure 2
Immunological survival of hMSC-EGFP cell transplants in rat spinal cord. (A) Histological assessment of hMSC-EGFP 
cell transplant survival in rat spinal cord without systemic immune suppression at five time points post transplantation (day 1 
and week 1–4). First row: hematoxylin-eosin (HE) staining indicating localisation and general appearance of transplantation site. 
Second row: direct EGFP fluorescence indicating the presence or absence of EGFP positive hMSC-EGFP cell transplants. Third 
row: immuno-histochemical staining for EGFP indicating the presence or absence of EGFP positive hMSC-EGFP cell transplants. 
Fourth row: immuno-histochemical staining for CD68 indicating macrophage infiltration into the transplantation site. All slides 
were examined using a conventional light/fluorescence microscope and digital pictures were taken under magnification as indi-
cated. Representative pictures were chosen from multiple hMSC-EGFP cell transplanted spinal cords analysed for day 1 (n = 2), 
week 1 (n = 2), week 2 (n = 2), week 3 (n = 2), and week 4 (n = 6) post-transplantation. (B) Molecular and histological assess-
ment of hMSC-EGFP cell transplant survival in rat spinal cord under systemic immune suppression (subcutaneous 10 mg/kg/day 
cyclosporin A) at four time points post transplantation (day 1 and week 1–3). DAY 1: Real-time RT-PCR analysis on mRNA 
isolated from hMSC-EGFP cell transplanted spinal cords on day 1 post-transplantation (n = 2) indicating the presence of EGFP 
mRNA transcripts in vivo in spinal cord following hMSC-EGFP cell transplantation. WEEK 1: direct EGFP fluorescence and 
immuno-histochemical staining for EGFP indicating the presence of EGFP positive hMSC-EGFP cell transplants on week 1 post-
transplantation. Representative pictures were chosen from multiple hMSC-EGFP cell transplanted spinal cords analysed 1 week 
post-transplantation (n = 5). WEEK 2: HE staining, direct EGFP fluorescence and immuno-histochemical staining for EGFP indi-
cating the presence of EGFP positive hMSC-EGFP cell transplants on week 2 post-transplantation. Representative pictures 
were chosen from multiple hMSC-EGFP cell transplanted spinal cords analysed 2 weeks post-transplantation (n = 3). WEEK 3: 
Standard PCR and RT-PCR analysis on DNA and mRNA isolated from hMSC-EGFP cell-transplanted spinal cords 3 weeks 
post-transplantation indicating the presence of EGFP DNA sequences and EGFP mRNA transcripts in vivo in spinal cord follow-
ing hMSC-EGFP cell transplantation.BMC Biotechnology 2007, 7:90 http://www.biomedcentral.com/1472-6750/7/90
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Transgene expression of hMSC-NT3-EGFP cell transplants 
in rat spinal cord
In a next attempt to genetically modify hMSC to produce
the NT3 neurothrophic factor, we used a DNA plasmid
encoding both the NT3 and EGFP protein (Figure 1A,
pIRES2-NT3-EGFP plasmid). Because transcription from
this plasmid results in the production of one mRNA
encoding both proteins, cell sorting for cells expressing
high levels of EGFP protein was used in order to obtain an
hMSC-NT3-EGFP line producing high levels of EGFP and
NT3 mRNA (Figure 1C, hMSC-NT3-EGFP cells) and EGFP
and NT3 protein (Figure 1D and 1E, hMSC-NT3-EGFP
cells). Following transplantation in rat spinal cord under
immune suppression, hMSC-NT3-EGFP cell transplants
were easily detectable by morphology on HE-stained
slides (Figure 4A). However, while expression of EGFP
was clearly demonstrated on day 1 post-transplantation
by direct fluorescence microscopy (data not shown) and
immuno-histochemical staining for EGFP, EGFP expres-
sion on week 1 post-transplantation, as demonstrated by
immuno-histochemical staining, was strongly decreased
and became almost undetectable by week 2 post-trans-
plantation (Figure 4A and 4B). This decrease in EGFP
expression was not due to lack of cell transplant survival
because cell transplants could clearly be visualized on HE-
stained slides (Figure 4A) and staining with an antibody
against human mitochondrial antigen confirmed the
human nature of the observed cell transplants (Figure 4A
and 4B). In addition, the observed EGFP transgene silenc-
ing in hMSC-NT3-EGFP cell transplants, but not in hMSC-
EGFP cell transplants, was further demonstrated by laser
capture micro-dissection (LCM) experiments. For this,
hMSC-EGFP and hMSC-NT3-EGFP cells were trans-
planted in rat spinal cord under immune suppression.
Next, at day 1 and day 7 post-transplantation, trans-
planted cell populations were isolated by LCM (Figure
5A) and the expression level of EGFP mRNA was analysed
by real-time PCR. As suggested by the results presented in
Figure 5B, while expression of EGFP mRNA by an hMSC-
EGFP cell transplant decreased by 50% at day 1 post-trans-
plantation as compared to cultured hMSC-EGFP cells,
EGFP mRNA by an hMSC-NT3-EGFP cell transplant
directly decreased by 80% at day 1 post-transplantation as
compared to cultured hMSC-NT3-EGFP cells. However,
while EGFP mRNA expression then remained stable
between day 1 and day 7 post-transplantation for an
hMSC-EGFP cell transplant, EGFP mRNA expression fur-
ther decreased between day 1 and day 7 post-transplanta-
tion for an hMSC-NT3-EGFP cell transplant. In summary,
based on the above-described results, we observed a simi-
lar degree of hMSC-NT3-EGFP cell transplant survival as
described above for hMSC-EGFP cell transplants, but
transgene expression by hMSC-NT3-EGFP cell transplants
rapidly declined in vivo.
Further investigation of transgene silencing in hMSC-NT3-
EGFP cell transplants
Since reproducible cell transplantation into spinal cord is
a relatively complex procedure, we first investigated
whether subcutaneous cell transplantation might provide
a valuable alternative in order to study persistence of
transgene expression in vivo. For this, hMSC-NT3-EGFP
cells were transplanted subcutaneously as described in the
Materials and Methods section. Unexpectedly and in con-
trast to the results described above, transgene silencing
did not occur in subcutaneous hMSC-NT3-EGFP cell
transplants. As demonstrated in Figure 6, no decrease in
EGFP expression was observed by direct EGFP fluores-
cence imaging and immuno-histochemical staining for
EGFP. The latter might suggest the presence of certain epi-
genetic regulatory mechanisms controlling transgene
expression in vivo in spinal cord. In order to investigate
this hypothesis, we assumed that in vivo epigenetic silenc-
ing of transgene expression is an irreversible process [25].
Thus, in case the observed transgene silencing is due to
epigenetic changes (eg DNA methylation and/or histone
modifications), a re-established hMSC-NT3-EGFP culture
from an EGFP-negative cell transplant should remain
EGFP-negative. For this, we re-established hMSC-NT3-
EGFP cultures following enzymatic disruption of the cel-
lular context of dissected spinal cords (including site of
cell transplantation) at week 2 post-transplantation.
When cultures were grown to confluence, the presence
and the level of EGFP expression of hMSC-NT3-EGFP was
investigated by FACS analysis. Figure 7 shows a represent-
ative FACS analysis of an established culture containing
both EGFP-positive and negative cells (Figure 7, SSC vs.
Transgene expression of hMSC-NT3 cell transplants in rat  spinal cord Figure 3
Transgene expression of hMSC-NT3 cell transplants 
in rat spinal cord. Molecular assessment of NT3 mRNA 
transcription by hMSC-NT3 cell transplants in rat spinal 
cord. Real-time RT-PCR analysis on mRNA isolated from 
hMSC-NT3 cell-transplanted spinal cords on day 1 post-
transplantation (n = 2) and on week 1 post-transplantation (n 
= 2) demonstrating the absence of detectable exogenous 
NT3 mRNA transcripts. SC: spinal cord.BMC Biotechnology 2007, 7:90 http://www.biomedcentral.com/1472-6750/7/90
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Transgene expression of hMSC-NT3-EGFP cell transplants in rat spinal cord Figure 4
Transgene expression of hMSC-NT3-EGFP cell transplants in rat spinal cord. (A) Histological assessment of EGFP 
expression by hMSC-NT3-EGFP cell transplants in rat spinal cord at three time points post transplantation (day 1, week 1 and 
week 2). First row: hematoxylin-eosin (HE) staining indicating localisation and general appearance of transplantation site. Sec-
ond row: immuno-histochemical staining for EGFP showing a decrease in EGFP expression over time by hMSC-NT3-EGFP cell 
transplants. Third row: immuno-histochemical staining for human mitochondrial antigen (hMA) indicating the human nature of 
the hMSC-NT3-EGFP cell transplants. Representative pictures were chosen from multiple hMSC-NT3-EGFP cell-transplanted 
spinal cords analysed 1 day (n = 7), 1 week (n = 11) and 2 weeks (n = 4) post-transplantation. (B) Detail image of the pictures 
described in part (A) of this figure.BMC Biotechnology 2007, 7:90 http://www.biomedcentral.com/1472-6750/7/90
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Analysis of transgene expression by hMSC-NT3-EGFP cell transplants following laser capture micro-dissection (LCM) Figure 5
Analysis of transgene expression by hMSC-NT3-EGFP cell transplants following laser capture micro-dissection 
(LCM). (A) Laser Capture Micro-dissection (LCM) of hMSC-NT3-EGFP cell transplants at day 1 and day 7 post-transplanta-
tion in rat spinal cord. Pictures showing cresyl-violet stained slides pre-and post-LCM. (B) Upper graph showing the level of 
transgenic EGFP mRNA transcripts/1000 copies GAPDH in hMSC-EGFP cell cultures (CELLS, n = 1), on transplanted hMSC-
EGFP cells at day 1 post-transplantation (DAY 1, n = 1), and on transplanted hMSC-EGFP cells at day 7 post-transplantation 
(DAY 7, n = 1). Lower graph showing the level of transgenic EGFP mRNA transcripts/1000 copies GAPDH in hMSC-NT3-
EGFP cell cultures (CELLS, n = 1), on transplanted hMSC-NT3-EGFP cells at day 1 post-transplantation (DAY 1, n = 1), and on 
transplanted hMSC-NT3-EGFP cells at day 7 post-transplantation (DAY 7, n = 1).BMC Biotechnology 2007, 7:90 http://www.biomedcentral.com/1472-6750/7/90
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EGFP dot plot). Further analysis revealed that the EGFP
positive cells were indeed hMSC-NT3-EGFP cells as they
stained positive for antibodies directed against human
CD29 and CD73, both markers present on parental
hMSC-NT3-EGFP cells (Figure 7, hCD29 vs. hCD73 dot
plot on EGFP-positive cells). EGFP-negative cells present
in the cultures displayed a clearly different morphology
(data not shown) and presumably were rat fibroblast cells
as they were not recognized by antibodies directed against
human CD29 and CD73 (Figure 7, hCD29 vs. hCD73 dot
plot on EGFP-negative cells). Based on the above-
described results, epigenetic modification is most likely
Transgene expression of subcutaneous hMSC-NT3-EGFP cell transplants Figure 6
Transgene expression of subcutaneous hMSC-NT3-EGFP cell transplants. Histological assessment of EGFP expres-
sion by subcutaneous hMSC-NT3-EGFP cell transplants at three time points post transplantation (day 1, week 1 and week 2). 
First row: hematoxylin-eosin (HE) staining indicating the presence of nucleated cells into the subcutaneously transplanted 
matrigel. Second row: direct EGFP fluorescence indicating the presence of EGFP positive hMSC-NT3-EGFP cell transplants. 
Third row: immuno-histochemical staining for EGFP indicating the presence of EGFP positive hMSC-NT3-EGFP cell transplants. 
Fourth row: immuno-histochemical staining for human mitochondrial antigen (hMA) indicating the human nature of the 
observed EGFP positive hMSC-NT3-EGFP cell transplants. Representative pictures were chosen from multiple subcutaneous 
hMSC-NT3-EGFP cell transplants analysed 1 day (n = 6), 1 week (n = 5) and 2 weeks (n = 3) post-transplantation.BMC Biotechnology 2007, 7:90 http://www.biomedcentral.com/1472-6750/7/90
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not causing the observed transgene silencing in intraspi-
nally transplanted hMSC-NT3-EGFP cells, and a putative
mechanism for this observed transgene silencing in
hMSC-NT3-EGFP cell transplants in spinal cord (Figure
4), but not subcutaneously (Figure 6), remains unclear.
Tumorigenicity of hMSC cell transplants in rat spinal cord
During progress in this study, we observed tumour growth
from on week 1 post-transplantation for both hMSC-
EGFP and hMSC-NT3-EGFP cell transplants in spinal cord
(see histological analysis on week 2 post-transplantation
in Figure 2B, Figure 4 and Figure 8). Because tumour
growth is a potential risk in clinical transplantation of
autologous, allogeneic and xenogeneic bone marrow-
derived stromal cell populations, we investigated whether
omitting immune suppressive therapy would be sufficient
to prevent further tumour growth and/or destroy malig-
nant cells. As shown in Figure 8, tumorigenic growth of
xenogeneic hMSC-EGFP cell transplants at week 2 post-
transplantation can efficiently be controlled by the host's
immune system. Two weeks following arrest of immune
suppressive therapy, the whole transplantation site is
invaded by macrophages and no viable cell EGFP+ trans-
plant could be observed.
Discussion
Stem cells, both embryonic and adult, are attractive targets
in the development of cell and gene therapy approaches
in a variety of diseases and injuries. While embryonic stem
cells have gained much interest due to their pluripotent
differentiation capacity, the potential clinical use of
multipotent adult stem cell populations in regenerative
medicine seems to be more realistic taking into account
certain immunological, practical and ethical advantages.
Currently, our research is focussing on the use of adult
bone marrow derived stromal cells (MSC) as a cellular
minipump for neurotrophic factors in injured spinal cord
in order to promote neural regeneration. In this context,
the aim of this study was to investigate the feasibility of a
plasmid-based strategy for genetic modification of human
(h)MSC with enhanced green fluorescent protein (EGFP)
and/or neurotrophin (NT)3, and to study in vivo cell sur-
vival and transgene expression of genetically modified
hMSC following transplantation in rat spinal cord.
In the first part of this study, we investigated survival of
hMSC-EGFP cell transplants in rat spinal cord in immune
competent and immune suppressed rats. Survival of
hMSC-EGFP in normal spinal cord of immune competent
rats was significantly compromised from an early time
point (day 1 post-transplantation) and resulted in total
graft eradication from on week 2 post-transplantation
(Figure 2A). However, suppressing the immune system
with cyclosporine A resulted in successful long-term in
vivo graft survival (Figure 2B). The observed immunologi-
cal rejection of MSC in the absence of systemic immune
suppression is in contrast to a large amount of literature
suggesting potential in vivo immune modulation and
Transgene expression of re-established hMSC-NT3-EGFP cultures from hMSC-NT3-EGFP cell transplanted spinal cords Figure 7
Transgene expression of re-established hMSC-NT3-EGFP cultures from hMSC-NT3-EGFP cell transplanted 
spinal cords. (A) Flow cytometric assessment of EGFP expression (Y-axis) by an established cell culture at passage 1 from dis-
sected hMSC-NT3-EGFP cell transplanted spinal cords showing the presence of both EGFP positive and EGFP negative cells. 
(B) Flow cytometric staining for human CD29 (X-axis) and human CD73 (= Y-axis) demonstrating that EGFP positive cells 
originate from hMSC-NT3-EGFP cell transplants while EGFP negative cells do not stain positive for human antibodies. Repre-
sentative flow cytometric data were chosen from multiple re-established hMSC-NT3-EGFP cell cultures (n = 3).BMC Biotechnology 2007, 7:90 http://www.biomedcentral.com/1472-6750/7/90
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immune privileged properties of MSC [21-24]. However,
we believe that there is a common misunderstanding
regarding the immune privileged nature of MSC. While
these cells have shown immune suppressive effects on
Graft-versus-Host disease when given intravenously as
shown in several publications, currently, as also demon-
strated by the presented results, there is no strong evi-
dence that these cells are of such an immune tolerant
nature that they can be transplanted in allogeneic and
xenogeneic hosts without giving proper immune suppres-
sion. The latter was recently also suggested by Eliopoulos
et al.[26], who clearly demonstrated that mice implanted
with MHC-mismatched MSC-expressing murine erythro-
poietin, in contrast to mice implanted with syngeneic
MSC-expressing erythropoietin, failed in causing a sus-
tained rise in hematocrit level. In addition, Swanger et
al.[27] demonstrated improved survival of transplanted
bone marrow stromal cells in spinal cord when using
high-dose cyclosporine A, indicating not only the impor-
tance of immune suppression, but also a link between cell
survival and level of immune suppression. Therefore,
based on these published reports and supported by our
findings, we conclude that xenogeneic hMSC cell trans-
plantation in rat is feasible and long-term transplant sur-
vival can be achieved under appropriate immune
suppression.
In the second part of this study, we investigated the stabil-
ity of EGFP or NT3 transgene expression by hMSC-EGFP,
hMSC-NT3 and hMSC-NT3-EGFP cell transplants in rat
spinal cord. While in vivo EGFP expression of transplanted
hMSC-EGFP cells was readily detectable at different time
points post-transplantation (Figure 2B), in vivo transgene
expression by hMSC-NT3 and hMSC-NT3-EGFP cells was,
respectively, undetectable (Figure 3) or declined rapidly
between day 1 and 7 post-transplantation (Figure 4). In
vivo transgene silencing is frequently reported and is cur-
rently considered as a major obstacle in the development
of ex vivo gene therapy protocols using stem cells. One
possible explanation for this transgene silencing might be
epigenetic modification of introduced transgenic DNA
sequences. Transgene silencing can be initiated and sus-
tained by: (i) methylation of CpG-rich DNA sequences
which inhibits RNA transcription, or (ii) deacetylation of
histones which allows DNA condensation and makes
DNA inaccessible for RNA transcription [28]. In our study,
we used an internal ribosome entry site (IRES)-based con-
struct for simultaneous expression of EGFP and NT3 pro-
Tumorigenicity of hMSC-EGFP cell transplants Figure 8
Tumorigenicity of hMSC-EGFP cell transplants. Left side: histological assessment of tumour growth by hMSC-EGFP cell 
transplants in rat spinal cord between day 1 and week 2 post-transplantation in immune suppressed animals (+ cyclosporine A). 
Right side: histological assessment of tumour regression in rat spinal cord at week 4 post-transplantation upon withdrawal of 
immune suppression at week 2 post-transplantation (-cyclosporine A). First row: hematoxylin-eosin (HE) staining indicating 
localisation and general appearance of transplantation site. Second row: direct EGFP fluorescence indicating the presence or 
absence of EGFP positive hMSC-EGFP cell transplants. Third row: immuno-histochemical staining for EGFP indicating the pres-
ence or absence of EGFP positive hMSC-EGFP cell transplants. Fourth row: immuno-histochemical staining for CD68 indicating 
macrophage infiltration into the transplantation site. Representative pictures were chosen from multiple hMSC-EGFP cell 
transplanted spinal cords analysed 1 day (n = 4), 2 weeks (n = 3) and 4 weeks (n = 2) post-transplantation.BMC Biotechnology 2007, 7:90 http://www.biomedcentral.com/1472-6750/7/90
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tein starting from a single messenger RNA. Others
previously reported similar transgene silencing when
using IRES-based constructs, however in vivo transgene
silencing could be reversed when animals were treated
with 5-azacytidine, a methyltransferase inhibitor [29]. In
addition, also deacetylase inhibitors (e.g. trichostatin A
and valproic acid) have demonstrated a capacity to pre-
vent transgene silencing in vitro and in vivo [30,31]. How-
ever, in a first trial experiment, neither in vitro treatment of
hMSC-NT3-EGFP cells, nor in vivo treatment of cell-trans-
planted rats, with 5-aza-2-deoxycytidine (a less toxic ana-
logue of 5-azacytidine [32]), trichostatin A or valproic
acid could reverse the observed transgene silencing in vivo
in spinal cord (data not shown). Next, further analysis
towards a putative explanation for the observed transgene
silencing indicated: (i) that transgene silencing did not
occur in subcutaneously transplanted hMSC-NT3-EGFP
cells (Figure 6), and (ii) that silenced transgene expression
was reactivated upon re-establishment of hMSC-NT3-
EGFP cultures out of cell-transplanted spinal cords (Figure
7). Based on these observations, we conclude that the
observed transgene silencing in our hMSC-NT3-EGFP cell
transplants is not due to epigenetic changes, but is most
likely due to a natural site-dependent adaptation of trans-
gene expression in vivo. Therefore, in order to use MSC or
fibroblast cell transplants as cellular minipumps, genetic
modification needs to result in sufficiently high transgene
expression able to persist even when cellular activity
might be reduced in spinal cord [19,33].
In the third part of this study, because we observed a
slowly progressing tumour growth following transplanta-
tion of all our hMSC cell transplants, we investigated
whether omitting immune suppressive therapy is suffi-
cient to prevent further tumour growth and to eradicate
malignant xenogeneic cell transplants. Despite some tum-
origenic characteristics of our hMSC cell transplants (high
degree of Ki67-positivity, multiple mitoses, central necro-
sis, neovascularisation,... (data not shown)), total regres-
sion was seen over a 2-week period after cessation of
systemic immune suppression. In addition, despite the
extent of the resulting inflammatory infiltration in the spi-
nal cord, we did not observe any influence on functional
behaviour of the animals (data not shown). Of note, the
observed tumour formation was not totally unexpected
given the fact that prolonged in vitro stem cell culture
might favour growth of MSC clones which potentially can
become tumorigenic in vivo as reported by several inves-
tigators [34-37]. This in vitro culture-based selection of
potentially tumorigenic MSC clones might indeed be a
serious problem when aiming transplantation of gene-
marked autologous or allogeneic MSC populations under
immune suppression, where the immune system will not
be able to control tumorigenicity. However, this does not
mean that all hMSC cultures will behave this way. Addi-
tional experiments that were performed with non-modi-
fied early passage hMSC cultures indicated excellent cell
survival with no signs of tumour formation upon trans-
plantation into healthy spinal cord (data not shown). The
absence of in vivo tumour formation for early passage
MSC cultures has also been reported by other investiga-
tors [34,37]. Therefore, based on these and other pub-
lished reports/reviews about mesenchymal stromal cells
[38] and supported by our findings, we conclude that new
techniques need to be developed in order to safely culture
and genetically modify hMSC cell transplants for research,
and eventually clinical applications.
Conclusion
In this study, we demonstrate that genetically modified
hMSC lines can survive in healthy rat spinal cord over at
least 3 weeks by using adequate immune suppression and
can serve as vehicles for transgene expression. However,
before genetically modified hMSC can potentially be used
in a clinical setting to treat spinal cord injury, more
research on standardisation of hMSC culture and genetic
modification needs to be done in order to prevent tumour
formation and transgene silencing in vivo.
Methods
Human bone marrow-derived stromal cells (hMSC)
Four cryopreserved human bone marrow-derived stromal
cell cultures used in a previously published study [39]
were thawed and cultured in complete culture medium
(CCM) consisting of Iscove's modified Dulbecco's
medium supplemented with 2 mM L-glutamine (IMDM;
Cambrex), 100 U/ml penicillin (Invitrogen), 100 mg/ml
streptomycin (Invitrogen), 1.25 mg/ml amphotericin B
(Invitrogen) and 10% fetal calf serum (FCS; Hyclone). In
one out of four cultures, outgrowths of one or more cells
lead to the establishment of an immortal bone marrow-
derived stromal cell line. This line was (i) analysed by
immunostaining and found to be CD166+, CD44+,
CD29+, CD73+, CD10+, HLA ABC+ and CD34-, CD45-,
MHCII-, CD31-, CD13-, and (ii) analysed by in vitro adi-
pogenic and osteogenic differentiation studies and found
to have lost their in vitro differentiation potential. This
parental line, designated as "hMSC", was further cultured
in CCM in T75 culture flasks (corning) at 37°C in a
humidified atmosphere supplemented with 5% CO2. For
splitting, cells were harvested once a week using Trypsin/
EDTA (Invitrogen) treatment and replated at a concentra-
tion of 6 × 103 cells/ml in 20 ml CCM in a new T75 culture
flask.
DNA plasmids
The following DNA plasmids were used in this study for
genetic modification of cultured hMSC: (i) the commer-
cially available pEGFP-N1 plasmid encoding the
enhanced green fluorescent protein (EGFP) (Clontech),BMC Biotechnology 2007, 7:90 http://www.biomedcentral.com/1472-6750/7/90
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the pCMV-NT3 plasmid encoding the rat neurothrophin-
3 (NT3) protein, and (iii) the pIRES2-NT3-EGFP plasmid
encoding rat NT3 and EGFP. The pCMV-NT3 plasmid was
constructed by replacing the IRES-EGFP sequence from
the pIRES2-EGFP plasmid (Clontech) with the rat NT3
cDNA (pAd-EF-NT3 plasmid, kindly provided by Prof.
HD Shine, Baylor College of Medicine, Houston, TX,
USA) [40]. The pIRES2-NT3-EGFP was constructed by
inserting the NT3 cDNA into the multiple cloning site of
the pIRES2-EGFP plasmid. After selection of successfully
ligated pCMV-NT3 and pIRES2-NT3-EGFP clones via
restriction digest mapping, several clones were confirmed
by sequence analysis. All plasmids were propagated in E.
coli supercompetent cells (Stratagene) and purified using
plasmid midiprep columns (Qiagen). Directly before use
in electroporation experiments, the plasmids were puri-
fied again using a PCR purification kit (Qiagen) and resus-
pended in DNA/RNA-free H2O at a concentration of 0.3
µg/µl.
Stable genetic modification of hMSC
Stable genetic modification of hMSC following plasmid
DNA electroporation was performed by culture under
combined antibiotics selection, fluorescence activated cell
sorting (FACS) and/or single cell cloning [41]. Briefly,
hMSC were harvested, washed twice with CCM, and resus-
pended at 5 × 106 cells/ml in OptiMem medium (Invitro-
gen) supplemented with 10% FCS. Next, 500 µl cell
suspension was mixed with 10 µg plasmid DNA in a 4
mm electroporation cuvette (Thermo Electron) and elec-
troporation at 260 V and 1050 µF was carried out using a
mammalian cell electroporation device (EquiBio). Fol-
lowing electroporation, cells were directly resuspended in
CCM and cultured for 48 hours. Next, medium was
changed to CCM supplemented with 250 µg/ml neomy-
cin-analogue G418 (Sigma) for 3–4 weeks of selection.
Next, in order to establish polyclonal "hMSC-EGFP" and
"hMSC-NT3-EGFP" lines, cells highly positive for EGFP
(highest 5%) were sorted twice using a FACS-Vantage cell
sorter (Becton Dickinson). For establishment of a clonal
"hMSC-NT3" line, single clones were grown and screened
for NT3 expression by ELISA and RT-PCR (see further). All
three lines were further cultured in CCM supplemented
with 250 µg/ml G418 in T75 culture flasks at 37°C in a
humidified atmosphere supplemented with 5% CO2. For
splitting, cell were harvested once a week using trypsin/
EDTA treatment and replated at a concentration of 6 ×
1003 cells/ml in 20 ml CCM in a new T75 culture flask.
Flow cytometry
Flow cytometric analysis was used for routine (weekly)
and pre-transplant measurement of EGFP transgene
expression and cell viability of harvested genetically mod-
ified hMSC populations. For this, a sample (0.5 × 106
cells) of harvested cells was resuspended in 1 ml CCM and
analysed for EGFP expression on a FACS-scan analytical
flow cytometer (Becton Dickinson). Cell viability was
measured after addition of 1 µl/ml propidiumiodide (1
mg/ml stock solution, Sigma) to the cell suspension
directly before flow cytometric analysis. In some experi-
ments, in order to discriminate hMSC within fibroblast/
neural cell cultures derived from dissected spinal cord (see
below), cell samples were stained with a phycoerythrin
(PE)-labelled monoclonal anti-human CD73 (Becton
Dickinson) and a PE-Cy5 labelled monoclonal anti-
human CD29 (Becton Dickinson) antibody. For this, cell
samples (1 × 106 cells/staining) were washed twice with
Phosphate Buffered Saline (PBS) supplemented with 1%
FCS, and resuspended in 100 µl PBS + 1% FCS. Next, 1 µg
of each antibody was added for 15 min., followed by a
washing step with PBS + 1% FCS. Finally, cells were resus-
pended in 1 ml PBS + 1% FCS and analysed on a FACS-
scan analytical flow cytometer.
ELISA
Secretion of the NT3 neurotrophic factor by hMSC-NT3
and hMSC-NT3-EGFP cells in vitro was determined using
the NT3 Emax ImmunoAssay Systems (Promega), accord-
ing to manufacturers' instructions.
Preparation of cell transplants
Following harvesting of hMSC-EGFP, hMSC-NT3 and
hMSC-NT3-EGFP cell populations via trypsin/EDTA treat-
ment, cells were washed twice with (PBS) supplemented
with 5% FCS. Next, cells (mean viability of cell popula-
tions: 75–90%) were resuspended in PBS + 5% FCS at a
concentration of 100 × 106 cells/ml for intraspinal cell
transplantation. Cell preparations were kept at room tem-
perature until injection. For subcutaneous transplanta-
tion, cells were resuspended in a cooled (1–4°C) Matrigel
solution (Becton Dickinson, dilution: 1/2 Matrigel + 1/2
PBS+5%FCS) at a concentration of 100 × 106 cells/ml.
Cell preparations were kept on ice until injection.
Animals
Female Wistar rats (n = 75, Charles River Laboratories),
starting weight 175–200 grams, were divided ad random
into different experimental groups. For all experiments,
rats were kept in normal day-night cycle (12/12) and got
food and water ad libitum. All experimental procedures
were approved by the "Ethical Committee for Animal
Experiments" of the Antwerp University (approval no.
2004/68).
Intraspinal cell transplantations
All surgical interventions were done under proper sterile
conditions. One hour before general induction, rats were
premedicated by subcutaneous (SC) injection of
buprenorphine (0.1 mg/kg), five minutes before skin inci-
sion cefazoline (25 mg/kg) was injected subcutaneouslyBMC Biotechnology 2007, 7:90 http://www.biomedcentral.com/1472-6750/7/90
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and repeated after 6 hours in order to prevent post-opera-
tive infections. Animals were then anaesthetized in an
induction chamber with a mixture of O2 and N2O (0.5 l/
min/1.0 l/min) and 4.0% isoflurane (Forene, Abbott).
During surgery, anaesthesia was maintained by using the
same mixture of O2 and N2O (0.5 l/min/1.0 l/min) and
0.75% isoflurane (Forene) by a face mask. After skin inci-
sion and spreading of the paraspinal muscles a laminec-
tomy was performed on Th10–Th11, using a 10× Zeiss
OpMi1 operation microscope. Afterwards an automatic
micro-injector pump (kdScientific) with 10 µl Hamilton
Microliter™ Syringe was positioned above the exposed
dura. A 33-Gauge Hamilton needle, attached to the
syringe was stereotactically placed through the intact dura
on midline position on a depth of 1.0 mm. After 2 min-
utes of pressure equilibration 5 µl cell suspension (con-
taining 5 × 105 cells) was injected over 5 minutes (1 µl/
min). Again a waiting period of 2 minutes with the needle
still in position in the spinal cord was used for pressure
equilibration and prevention of backflow of cell suspen-
sion. Muscle and skin was closed with respectively Vicryl
(Ethicon) and staplers after proper desinfection of the
operation field. Postoperative application of 10 ml glu-
cose 5% solution prevented possible dehydration. During
surgery, body temperature was kept on 37% by using a
heating path with feedback control by an intrarectal
placed sensor. Operated animals recovered by a 5 minutes
period of 100% O2 and were placed individually in plastic
cages till day 1 postoperative with ad libitum water and
food. Skin staplers were removed 6 days post-operative.
Daily follow-up was done by measuring weight and
assessment of general health status. During the entire
experiment, immune mediated rejection of cell trans-
plants was prevented by daily subcutaneous injections of
10 mg/kg cyclosporine A.
Subcutaneous cell transplantations
Subcutaneous injections were done in the interscapular
region. After shaving the region of interest, 300 µl of fluid
matrigel-cell suspension was injected after which the
matrigel immediately coagulated to a palpable subcutane-
ous tumour. During the entire experiment, immune medi-
ated rejection of cell transplants was prevented by daily
subcutaneous injections of 10 mg/kg cyclosporine A.
Spinal cord dissection for molecular and cellular analysis
At different time points post-transplantation, animals
were re-anaesthetised as described above. After exposing
the cell injection site, an expansion of the previous lami-
nectomy of Th10 was performed to a total of three thora-
cal levels (e.g. Th 9–10–11). The spinal cord was cut 5 mm
cranial and 5 mm caudal from the injection site. This 10
mm section was then extracted and further processed. (i)
For standard and real-time PCR/RT-PCR analysis on
whole spinal cord sections, the extracted spinal cord sec-
tions were preserved in RNAlater (Ambion), as described
by the manufacturers' instructions, until further process-
ing (see below). (ii) For gene expression analysis follow-
ing Laser Capture Micro-dissection (LCM), extracted
spinal cord sections were immediately frozen into liquid
nitrogen and stored at -80°C until further processing (see
below). (iii) For cellular analysis of transplanted cell pop-
ulations, extracted spinal cord sections were washed in
PBS and incubated for 90 min in a 0.1% collagenase
(Sigma) solution dissolved in PBS. Next, dissociated cells
were plated in CCM in T75 culture flasks. When cultures
reached confluence, human cells were stained with anti-
bodies against human CD73 and CD29 and analysed for
EGFP expression using a FACS-scan analytical flow cytom-
eter (see above).
Spinal cord dissection for histological analysis
Rats were deeply anaesthetized by intraperitoneal injec-
tion of sodium pentobarbital (90 mg/kg) and then per-
fused transcardially with 150 ml heparinised (1 U/ml)
NaCl 0.9%, followed by 300 ml of cold buffered parafor-
maldehyde 4% (pH 7.4) over a period of 25 min. The spi-
nal cord was than excised from low lumbal towards high
cervical level, including the injection site, and immersed
for an additional 2 hours in the same fixative.
Matrigel dissection
Subcutaneously placed matrigels were removed under gas
anaesthesia and processed for molecular or histological
analysis as described above.
Standard and real-time PCR/RT-PCR analysis on cells and 
whole spinal cord sections
Genetically modified hMSC cell cultures and dissected
spinal cord sections were processed for simultaneous
DNA and RNA isolation using an AllPrep DNA/RNA Mini
Kit (Qiagen), as described by the manufacturers' instruc-
tions. Following spectrophotometric quantification, iso-
lated DNA was directly used for further PCR analysis.
Isolated RNA was first reverse-transcribed into cDNA for 1
hour using an Omniscript RT kit (Qiagen), as described by
manufacturers' instructions. Next, both DNA and cDNA
was analysed for the presence of GAPDH, EGFP and NT3
sequences by standard PCR on a Thermocycler Px2
machine (Thermo Cycler) or by real-time PCR on an iCy-
cler Thermal Cycler machine (Biorad). The following
primer pairs were used for specific amplification: for
GAPDH forward 5'-ACC ACA GTC CAT GCC ATC AC-3'
and reverse 5'-TCC ACC ACC CTG TTG CTG TA-3' (this
primer pair recognizes both rat and human GAPDH
sequences), for EGFP forward 5'-AGA ACG GCA TCA AGG
TGA AC-3' and reverse 5'-TGC TCA GGT AGT GGT TGT
CG-3', and for NT3 forward 5'-GAT CCA GGC GGA TAT
CTT GA-3' and reverse 5'-AAT CAT CGG CTG GAA TTC
TG-3' (combination of this primer pair recognizes rat NT3BMC Biotechnology 2007, 7:90 http://www.biomedcentral.com/1472-6750/7/90
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sequences, not human NT3 sequences; used for results
described in Figure 1B) or reverse 5'-CTT ATC ATC GTC
ATC CTT GTA GTC-3' (use of the latter primer recognizes
a FLAG sequence on transgenic rat NT3 sequences, not on
endogenous rat NT3 sequences; used for results described
in Figure 1C and Figure 3). Standard PCR reactions were
setup using a Taq PCR Core Kit (Qiagen) and real-time
PCR reactions were setup in duplicate using a SYBR Green
ER qPCR Supermix (Invitrogen), both according to the
manufacturers' instructions. Reactions were carried out as
follows: after an initial denaturation step at 94°C for 4
min., amplifications consisted of 30 (standard PCR) or 60
(real-time PCR) cycles of denaturation at 95°C for 1 min.,
annealing at 56°C for 1 min. and extension at 72°C for 1
min. PCR products obtained after standard PCR were ana-
lysed in a 1% agarose gel stained with 0.5 µg/ml ethid-
iumbromide and visualised by UV light. For analysis of
real-time PCR data, expression levels of EGFP and NT3
were calculated versus expression of GAPDH.
Gene expression analysis following laser capture micro-
dissection (LCM)
Frozen spinal cords were embedded in Neg-50™ (Richard-
Allan Scientific) and 8 µm thick sections were cut using a
cryomicrotome (Microm HM 500). These sections were
then caught on a PEN-membrane, stretched on a metal
frame, and instantly fixed with a 70% ethanol solution to
inhibit RNA degradation. Next, sections were stained with
cresyl-violet (LCM Staining Kit, Ambion) and dried in
xylene. During the cutting process, some sections were
stained with hematoxylin-eosin to verify the presence of
the injected cells. The frames were sandwiched with an
RNase-free slide and mounted on the LCM microscope
(SL µCut, MMI). Areas with cells of interest in a range
from 0.5 mm2 to 1.5 mm2 were selected with a software
interface at 400× magnification and cut with a UV-laser.
RNA was extracted using the Picopure™ RNA Isolation kit
(Arcturus), and the RNA quality was assessed using the
Agilent 2100 BioAnalyzer (Agilent Technologies). The
overall RNA quality was very good and the calculated
yields ranged from 3 – 10 ng of total RNA. RNA was
reverse transcribed using the Sensiscript RT Kit (Qiagen).
Real-Time PCR was carried out in triplicate on an ABI
Prism 7700 Sequence Detection System (Applied Biosys-
tems) using a custom Taqman™ Primers-Probes set for the
EGFP gene and a Primers-Probe set for GAPDH as house-
keeping gene. Real-time PCR amplification was carried
out using following scheme: 2 initial steps of 2 min at
50°C and 10 min at 95°C, then 55 amplification loops
with a denaturation of 1 sec at 95°C and an annealing and
extention phase of 1 min at 60°C in a reaction volume of
25 µL.
Histological analysis
Fixed spinal cord segments and matrigels were dehydrated
in sucrose gradients (5%, 10% and 20%), frozen in liquid
nitrogen and stored at -80°C until further processing.
Consecutive 10 µm-thick longitudinal cryosections were
cut using a Microm HM5000 cryostat and stained with
hematoxylin-eosin (HE) to locate the transplantation site.
Further immunohistochemical analysis were done using
either a mouse anti-human mitochondrial antigen (hMA)
monoclonal antibody (Chemicon, MAB1273, 1/50 dilu-
tion) for human cell identification, a goat anti-EGFP pol-
yclonal antibody (Abcam, AB6673, 1/1200 dilution) to
detect EGFP transgene expression by hMSC cell trans-
plants, and a mouse anti-rat CD68 monocyte/macro-
phage monoclonal antibody (Chemicon, MAB1435, 1/
150 dilution) to detect macrophage infiltration into the
transplantation site. In brief, slides were rinsed with a
commercial washing buffer (DAKO S3006) and endog-
eneous peroxidase sites were blocked following 30 min
incubation with methanol + 1% hydrogen peroxide. Next,
slides were washed with water and washing buffer, fol-
lowed by incubation with normal serum for 1 hour at
room temperature (species dependent on the secondary
antibody; normal goat serum (Dako, X0907) for staining
with MAB1435 and normal rabbit serum (Dako, X0902)
for staining with AB6673 and MAB1273). Subsequently
slides were incubated overnight at 4°C with the primary
antibody. Following this, slides were rinsed with washing
buffer and incubated for 1 hour at room temperature
either with peroxidase-coupled rabbit anti-goat Ig anti-
body (Rockland, 605-4302, 1/200 dilution) to detect
EGFP, with peroxidase-coupled goat anti-mouse Ig anti-
body (Rockland, 610-1319, 1/200 dilution) to detect
CD68, or with biotin-coupled rabbit anti-mouse Ig
(Abcam, ab67271, 1/200 dilution) to detect hMA. For the
latter, an extra incubation step with a HRP-coupled
streptavidin based detection complex (StreptABComplex,
Dako) was required and performed as described in the
manufacturers' instructions. Visualisation for all slides
was carried out after staining with DAB (Diaminobenzi-
dine, Dako), according to manufacturers instructions, and
nuclei were counterstained with hematoxylin carazzi. Flu-
orescence imaging (standard 2000 ms exposure time) and
bright-field immuno-histochemical analysis was done
using an Olympus Bx41 microscope equipped with an
Olympus DP50 camera. Olympus DP Software was used
for image collection and Photoshop for image processing.
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